The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy.
1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.
1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
Pergamino, Buenos Aires, Argentina
CABA, Argentina
La Rioja, Argentina
La Rioja, Argentina
La Rioja, Argentina
La Rioja, Argentina